Fibronib 150 Capsule contains Nintedanib 150mg, a potent tyrosine kinase inhibitor used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Nintedanib works by blocking multiple pathways involved in the abnormal growth of fibroblasts and tumor cells, thereby slowing disease progression. This medication is indicated for patients diagnosed with IPF to reduce lung function decline and improve quality of life. Additionally, Fibronib 150 is prescribed as part of combination therapy for advanced NSCLC, particularly in cases with adenocarcinoma histology after first-line chemotherapy. The capsule should be taken orally, preferably with food to minimize gastrointestinal side effects such as diarrhea, nausea, and abdominal pain. Patients should be monitored regularly for liver function abnormalities, bleeding risks, and gastrointestinal perforations, as these are potential adverse effects associated with Nintedanib. It is contraindicated in patients with known hypersensitivity to the drug or its components. Caution is advised in patients with hepatic impairment or those on anticoagulant therapy. Fibronib 150 Capsule should be used under strict medical supervision, with adherence to prescribed dosage to maximize therapeutic benefits while minimizing risks.